Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases

Li Jiao; Shougang Guo; Shougang Guo

doi:10.3389/fimmu.2022.966766

Frontiers in Immunology (Oct 2022)

Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases

Li Jiao,
Shougang Guo,
Shougang Guo

Affiliations

Li Jiao: Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
Shougang Guo: Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
Shougang Guo: Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

DOI: https://doi.org/10.3389/fimmu.2022.966766
Journal volume & issue: Vol. 13

Abstract

Read online

Current treatments for central nervous system (CNS) inflammatory demyelinating diseases (IDDs) include corticosteroids, plasma exchange, intravenous immunoglobulin, and immunosuppressant drugs. However, some patients do not respond well to traditional therapies. In recent years, novel drugs, such as monoclonal antibodies, targeting the complement component C5, CD19 on B cells, and the interleukin-6 (IL-6) receptor, have been used for the treatment of patients with refractory CNS IDDs. Among these, tocilizumab and satralizumab, humanized monoclonal antibodies against the IL-6 receptor, have shown beneficial effects in the treatment of this group of diseases. In this review, we summarize current research progress and prospects relating to anti-IL-6 therapies in CNS IDDs.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords